
Pharmaceutical company AstraZeneca has announced they will partner with US-based AI biologics firm, Absci, to design an antibody for cancer.
The collaboration aims to create a zero-shot generative AI model, which would work on creating new antibody therapeutics and enhancing the existing ones.